跳至主要内容
临床试验/CTRI/2010/091/000296
CTRI/2010/091/000296已完成3 期

Evaluation of efficacy and safety of opipramol versus alprazolam in the treatment of generalized anxiety disorder: a randomized, open label, active controlled, multicentric study.

Sun Pharmaceutical Industries Ltd.0 个研究点目标入组 200 人开始时间: 待定最近更新:

试验速览

阶段
3 期
状态
已完成
入组人数
200

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

入选标准

  • 1. Male or female patients aged between 18 and 65 years.
  • 2. Patient has a primary diagnosis of generalized anxiety disorder according to Diagnostic and Statistical Manual of Mental disorder IV Text Revision (DSM-IV TR) (See Appendix-I).
  • 3. Patients having total score of minimum of 17 on Hamilton Rating Scale of Anxiety.
  • 4. Patient willing to give their informed consent.

排除标准

  • 1. Pregnant, lactating women or women of childbearing age who are not using an acceptable method of birth control.
  • 2. Patients with known hypersensitivity to Opipramol (G3040) or Alprazolam (U31889) or any of the excipients of this formulation.
  • 3. Patients taking MAO inhibitors.
  • 4. Patients with acute narrow angle glaucoma.
  • 5. Patients with prostate hypertrophy.
  • 6. Alcohol abused patients.
  • 7. Patients having severe renal and hepatic impairment.
  • 8. Patients who displayed marked suicidal intent or known suicidal tendencies.

研究者

相似试验